M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project PharmaTimesPartnership grants Lilly global rights to Alzstatin ACD680NeuroscienceRead full story pharminent June 9, 2026 (Last updated: June 9, 2026) PharmaTimes Partnership grants Lilly global rights to Alzstatin ACD680 Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill dataNext: Cancer biotech Parabilis books record IPO, raising $670m Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
